Analyst Ratings For Anika Therapeutics Inc (NASDAQ:ANIK)
Today, Anika Therapeutics Inc (NASDAQ:ANIK) stock was downgraded by First Analysis from Outperform to Neutral with a price target of $37.00.
There are 1 Hold Ratings, 1 Buy Ratings, no Strong Buy Ratings, no Sell Ratings on the stock.
The current consensus rating on Anika Therapeutics Inc (NASDAQ:ANIK) is Buy with a consensus target price of $42.50 per share, a potential 4.96% upside.
Some recent analyst ratings include
- 2/22/2019-Anika Therapeutics Inc (NASDAQ:ANIK) gets downgraded to Neutral by First Analysis with a price target of $37.00
- 7/27/2018-Anika Therapeutics Inc (NASDAQ:ANIK) gets upgraded to Outperform by Barrington Research with a price target of $48.00
- 1/26/2018-Anika Therapeutics Inc (NASDAQ:ANIK) has coverage initiated with a Buy rating
- On 11/30/2017 Richard Hague, Insider, sold 5,250 with an average share price of $54.48 per share and the total transaction amounting to $286,020.00.
- On 10/23/2017 Charles H Sherwood, CEO, sold 22,228 with an average share price of $60.06 per share and the total transaction amounting to $1,335,013.68.
- On 10/20/2017 Charles H Sherwood, CEO, sold 5,991 with an average share price of $60.04 per share and the total transaction amounting to $359,699.64.
- On 10/16/2017 Charles H Sherwood, CEO, sold 3,293 with an average share price of $60.04 per share and the total transaction amounting to $197,711.72.
- On 10/13/2017 Charles H Sherwood, CEO, sold 7,124 with an average share price of $60.08 per share and the total transaction amounting to $428,009.92.
- On 7/27/2017 Charles H Sherwood, CEO, sold 63,799 with an average share price of $50.79 per share and the total transaction amounting to $3,240,351.21.
- On 7/5/2017 Charles H Sherwood, CEO, sold 14,201 with an average share price of $50.03 per share and the total transaction amounting to $710,476.03.
About Anika Therapeutics Inc (NASDAQ:ANIK)
Anika Therapeutics, Inc., together with its subsidiaries, provides orthopedic medicines for patients with degenerative orthopedic diseases and traumatic conditions in the United States and internationally. The company develops, manufactures, and commercializes therapeutic products based on its proprietary hyaluronic acid (HA) technology. Its orthobiologics products comprise ORTHOVISC, ORTHOVISC mini, MONOVISC, and CINGAL for the treatment of osteoarthritis of the knee; HYALOFAST, a biodegradable support for human bone marrow mesenchymal stem cells used for cartilage regeneration and as an adjunct for microfracture surgery; HYALONECT, a resorbable knitted fabric mesh; HYALOSS used to mix blood/bone grafts to form a paste for bone regeneration; and HYALOGLIDE, an ACP gel used in tenolysis treatment. The company's dermal products include wound care products that comprise HYALOMATRIX and HYALOFILL for the treatment of complex wounds, such as burns and ulcers, and for use in connection with the regeneration of skin; and ELEVESS, an aesthetic dermatology product. Its surgical products comprise HYALOBARRIER, a post-operative adhesion barrier for use in the abdomino-pelvic area; INCERT, a HA product used for the prevention of post-surgical spinal adhesions; MEROGEL, a woven fleece nasal packing; and MEROGEL INJECTABLE, a viscous hydrogel. The company also offers ophthalmic products, including injectable HA products that are used as viscoelastic agents in ophthalmic surgical procedures, such as cataract extraction and intraocular lens implantation; and veterinary products, which include HYVISC, an injectable HA product for the treatment of joint dysfunction in horses. Anika Therapeutics, Inc. has a strategic collaboration with the Institute for Applied Life Sciences at the University of Massachusetts Amherst to develop a therapy for rheumatoid arthritis. The company was founded in 1983 and is headquartered in Bedford, Massachusetts.
Recent Trading Activity for Anika Therapeutics Inc (NASDAQ:ANIK)
Shares of Anika Therapeutics Inc closed the previous trading session at 40.49 up +0.44 1.10% with 40.03 shares trading hands.
